Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9401161 | 0.91 | MTNR1A (0.84) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| Luzindole SCHEMBL9118261 | 0.90 | MEN1 (0.81) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL9751553 | 0.88 | MTNR1A (0.79) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL9401112 | 0.88 | MTNR1A (0.79) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL9302251 | 0.87 | MTNR1A (0.77) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL9304093 | 0.86 | MTNR1A (0.75) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL9304037 | 0.84 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL9303475 | 0.84 | MTNR1A (0.72) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL1626901 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL9302872 | 0.83 | MTNR1A (0.71) | MTNR1AMTNR1BCYP1A2CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5283343-A | Melatonin antagonists | WHITBY RESEARCH, INC. (US) | 1994-02-01 | — | — | US | claimed |
| JP-4173777-A | — | — | None | — | — | JP | disclosed |
| EP-4618962-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Onconova Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4551578-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| EP-4532503-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| EP-4526289-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4502609-A2 | DETERMINING A CIRCADIAN RHYTHM | Vanda Pharmaceuticals Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12201604-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2024259241-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-0549916-A2 | Compounds useful as antiproliferative agents | WHITBY RESEARCH, Inc. (US) | 1993-07-07 | — | — | EP | disclosed |
| US-5206377-A | Compounds useful as antiproliferative agents | WHITBY RESEARCH, INC. (US) | 1993-04-27 | — | — | US | disclosed |
| US-5151446-A | Neurological disorders or cardiovascular disorders | NORTHWESTERN UNIVERSITY (US) | 1992-09-29 | — | — | US | disclosed |
| JP-H04173777-A | MELATONINE ANALOGUE | WHITBY RES INC | 1992-06-22 | — | — | JP | disclosed |
| US-5093352-A | Melatonin inhibitor, sleep, 2-aryl N-acetyl tryptamine | WHITBY RESEARCH, INC. (US) | 1992-03-03 | — | — | US | disclosed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | disclosed |
| EP-0375726-A4 | MELATONIN ANALOGUES | — | 1991-01-30 | — | — | EP | disclosed |
| EP-0375726-A1 | MELATONIN ANALOGUES | Whitby Research Incorporated (US) | 1990-07-04 | — | — | EP | disclosed |
| WO-1989001472-A1 | MELATONIN ANALOGUES | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1989-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201604-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP1A2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.